# A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol

> **NCT04039919** · PHASE1 · TERMINATED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 40 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Padsevonil
- **DRUG:** Placebo (PSL)

## Key facts

- **NCT ID:** NCT04039919
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-17
- **Primary completion:** 2020-05-22
- **Final completion:** 2020-05-22
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04039919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04039919, "A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04039919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*